ImmunoPrecise Antibodies Ltd. (IPA)

Market Cap	91.85M
Revenue (ttm)	17.74M
Net Income (ttm)	-21.88M
Shares Out	46.15M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	392,158
Open	2.020
Previous Close	2.020
Day's Range	1.915 - 2.050
52-Week Range	0.270 - 2.410
Beta	0.55
Analysts	Strong Buy
Price Target	4.00 (+101.01%)
Earnings Date	Sep 15, 2025

About IPA

ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: IPA
• Website: https://www.ipatherapeutics.com

Financial Performance

In 2025, ImmunoPrecise Antibodies's revenue was 24.52 million, an increase of 0.01% compared to the previous year's 24.52 million. Losses were -30.23 million, 15.8% more than in 2024.

Financial numbers in CAD

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 101.01% from the latest price.

Price Target

$4.0

(101.01% upside)

Analyst Consensus: Strong Buy